Sermorelin & Ipamorelin

Description

Sermorelin & Ipamorelin Blend
Both Ipamorelin & Sermorelin are synthetic peptides, and when blended, they may act synergistically to further their individual potential impacts. More specifically, they both appear to upregulate the production of growth hormone. The growth hormone appears to play a vital role in accelerating growth and is considered to function primarily to regulate metabolic functions.
Overview
Sermorelin & Ipamorelin are synthetic peptides, where Sermorelin is composed of 29 amino acids(1) and Ipamorelin is composed of 5 amino acids.(2) Sermorelin seems to serve as a functional equivalent to the naturally occurring growth hormone-releasing hormone (GHRH). Unlike GHRH, which consists of 44 amino acids, Sermorelin is shortened to a sequence of 29 amino acids. This truncated form is also referred to as Growth Hormone Releasing Factor (1-29) or simply GRF (1-29).
Ipamorelin was the first synthetic GHS discovered with a proposed high selectivity towards the growth hormone receptors without apparently affecting the synthesis of other pituitary hormones such as ACTH and prolactin.(3)
Sermorelin is also known as GHRF (1-29) amide, and the potential of this fragment was first investigated in the early 1980s. It was suggested that upon introduction, Sermorelin may exhibit affinity towards the GHRH receptors located at the pituitary gland and possibly stimulate the secretion of growth hormone.(4)
Both Ipamorelin & Sermorelin are posited to produce action on the pituitary gland. Upon binding, these peptides are suggested to stimulate the pituitary gland and secrete more growth hormone.(4)(5)
The difference in their mode of action is the pathway by which they exert their action. Sermorelin appears to affect the GHRH receptors while Ipamorelin appears to act via the ghrelin pathway.(5) Thus, it is believed that Sermorelin may retain the core ability of GHRH: to potentially prompt the GHRH receptors in the pituitary gland to intermittently release growth hormone. This action is thought to subsequently elevate levels of insulin-like growth factor-1 (IGF-1), which is viewed as the primary agent responsible for the anabolic action of growth hormone. Ipamorelin does not appear to work via the GHRH receptors. Instead, this synthetic pentapeptide is under investigation for its potential capabilities as a growth hormone secretagogue (GHS). It is thought to function similarly to Growth Hormone Releasing Peptides (GHRPs) and may potentially mimic the natural action of the hunger hormone, ghrelin. The peptide is suspected to target ghrelin receptors in the anterior pituitary gland, also known as Growth Hormone Secretagogue Receptors 1 Alpha (GHS-R1a). This characteristic positions Ipamorelin as a highly selective secretagogue and a potent agonist for the growth hormone/ghrelin secretagogue receptor.
Since the mode of action of both the peptides appears to be different, they may complement each other when presented together and thereby provide a potentially greater growth hormone response.
A major difference between the two peptides appears to be their respective half-lives, where the half-life of Sermorelin is considered to be 11 to 12 minutes and that of Ipamorelin is approximately 2 hours.(6)
Therefore, research has posited that Sermorelin may trigger an immediate growth hormone response while Ipamorelin may extend this process for longer periods.